Novak Srdan
Odjel za reumatologiju i klinicku imunologiju, Klinika za internu medicinu, Klinicki bolnicki centar Rijeka, Kresimirova 42, 51000 Rijeka.
Reumatizam. 2012;59(2):53-7.
Antysynthetase syndrome is considered as a group ofidiopathic inflammatory myositis with charcteristic serologic hallmark--antibodies which recognise the aminoacyl-tRNA synthetasses (ARS). Clinical picture of those patients contains myositis and/or intersticial lung disease (ILD) and/or arthritis and/or fever and/or Raynaud phenomenon and sometimes characteristic look of mechanic's hands. Myositis can be overt, sometimes even absent, while IBP is major cause of morbidity and determines the outcome of the disease. Untill now eight different any-synthetase autoantibodies are recognised, and most frequent are findings of anti-histidyl-tRNa synthetase antibodies. Patients with other ARS autoantibodies usually have severe ILD. Drug of choice are steroids in dosage of 1 mg/kg with immunosupresive agent (azatioprin or methotrexate) while in severe IBP cyclophosphamide is needed. Recently succsesful treatment with rituximab in combination with cyclophosphamide is reported.
抗合成酶综合征被认为是一组特发性炎性肌病,具有特征性的血清学标志——识别氨酰 - tRNA合成酶(ARS)的抗体。这些患者的临床表现包括肌炎和/或间质性肺病(ILD)和/或关节炎和/或发热和/或雷诺现象,有时还有特征性的技工手外观。肌炎可能明显,有时甚至不存在,而间质性肺病是发病的主要原因并决定疾病的结局。到目前为止,已识别出八种不同的抗合成酶自身抗体,最常见的是抗组氨酰 - tRNA合成酶抗体的检测结果。患有其他ARS自身抗体的患者通常有严重的ILD。首选药物是剂量为1mg/kg的类固醇与免疫抑制剂(硫唑嘌呤或甲氨蝶呤),而在严重的间质性肺病中需要环磷酰胺。最近有报道称利妥昔单抗联合环磷酰胺治疗成功。